ReviewFrontiers in neurology2019
Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 86 citations in OpenAlex.
- Diagnostic Delay in Multiple Sclerosis in China: A Nationwide Cross-Sectional Study.Advances in therapy · 2026Article
- Applying the 2024-revised McDonald criteria for multiple sclerosis using conventional diagnostic tools: a single-centre prospective cohort study in Germany.EClinicalMedicine · 2026Article
- Deep learning-based neuroanatomical profiling reveals population-specific brain changes in multiple sclerosis: a large-scale Middle Eastern study.BMC medical imaging · 2026Observational
- The Relationship Between Inflammation and Central Nervous System in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Prevalence, Incidence, and Risk of Different Comorbidity Categories in Pediatric Multiple Sclerosis: A Systematic Review and Meta-Analysis Protocol.Children (Basel, Switzerland) · 2026Article
- Kappa index: real-world study for assessing cut-off values that provide the best accuracy for multiple sclerosis diagnosis in patients with CIS.Frontiers in immunology · 2026Article
- Machine learning-based combination of the central vein sign, cortical lesions and paramagnetic rim lesions: a web-based tool for the diagnosis of multiple sclerosis.Brain communications · 2026Article
- Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.Journal of neurology · 2025Article
- The Utility of Intravoxel Incoherent Motion Metrics in Assessing Disability in Relapsing-Remitting Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2025Article
- Conventional and Advanced Magnetic Resonance Imaging Biomarkers of Multiple Sclerosis in the Brain.Cureus · 2025Review
- Induction of Antigen-Specific Tolerance in a Multiple Sclerosis Model without Broad Immunosuppression.ACS nano · 2025Article
- Rising Prevalence of Multiple Sclerosis in Switzerland: Results from the Swiss Multiple Sclerosis Registry.Neuroepidemiology · 2025Article
- Incorporation of the central vein sign into the McDonald criteria.Multiple sclerosis and related disorders · 2025Article
- Pediatric Neuroimaging of Multiple Sclerosis and Neuroinflammatory Diseases.Tomography (Ann Arbor, Mich.) · 2024Review
- The prevalence of multiple sclerosis in Israel based on validation of a health care organization database.Scientific reports · 2024Article
- Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.Journal of neurology · 2024Review
- Breaking boundaries: the transformative role of exercise in managing multiple sclerosis.EXCLI journal · 2024Review
- Building digital patient pathways for the management and treatment of multiple sclerosis.Frontiers in immunology · 2024Review
- Multiple Sclerosis: New Insights into Molecular Pathogenesis and Novel Platforms for Disease Treatment.Current drug research reviews · 2024Review
- Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?Therapeutic advances in neurological disorders · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is a chronic immune mediated demyelinating disease leading to neurological disabilities that need to be diagnosed and treated early. Guidelines on multiple sclerosis diagnosis and monitoring experienced comprehensive changes over the last decades. The first McDonald criteria published in 2001 emphasized the importance of MR imaging but also recognized the role of cerebrospinal fluid diagnostics. The demonstration of an intrathecal immunoglobulin G synthesis is a well-established additional component and has a long tradition in the diagnosis of relapsing-remitting multiple sclerosis. However, the role of cerebrospinal fluid for diagnostic purposes was rather diminished in each revision of the McDonald criteria. In the latest revision of the McDonald criteria of 2017, the detection of an intrathecal immunoglobulin G synthesis as oligoclonal bands experienced a revival. Patients with the first clinical event suggesting multiple sclerosis who fulfill the criteria for dissemination in space can be diagnosed with relapsing-remitting multiple sclerosis when oligoclonal bands in cerebrospinal fluid are detected. The diagnostic sensitivity of these novel criteria with a focus on dissemination in time and oligoclonal bands as a substitute for dissemination in time was published in different cohorts in the last year and is of special interest in this review. Recently published data show that by applying the 2017 McDonald criteria, multiple sclerosis can be diagnosed more frequently at the time of first clinical event as compared to the 2010 McDonald criteria. The main effect was due to the implementation of oligoclonal bands as a substitute for dissemination in time. However, careful differential diagnosis is essential in patients with atypical clinical manifestations to avoid misdiagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.